Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
UNKNOWNN/A

INflammation and Small Vessel Disease Study

Sponsor: University of Cambridge

NCT ID: NCT05746221

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Health checks and monitoring — no treatment given
Type of study
Observational (no treatment given)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Not specified by the sponsor
How long the study runs
Study runs about 47 months (dates as stated)
About the drug or intervention
Not specified by the sponsor
Patient visit burden
Not specified by the sponsor
Type of study
Observing health over time
Ages
40 Years and over
Who
All
Number of participants
200
Started
2022-08-10
Last checked
2023-02

Plain English Summary

What is this study?

  • • Testing a new treatment for cerebral small vessel diseases
  • • Clinical study - 200 participants
  • • A prospective observational cohort study in patients with cerebral small vessel disease deterring whether changes in systemic inflammation predict brain white matter damage measured using MRI and cognitive decline

Who can take part?

  • • Ages 40 Years and over
  • • Diagnosed with cerebral small vessel diseases

Where?

  • • Cambridge - University of Cambridge

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

A prospective observational cohort study in patients with cerebral small vessel disease deterring whether changes in systemic inflammation predict brain white matter damage measured using MRI and cognitive decline. This is a study funded by a joint BHF-Dutch Heart Foundation research grant and will be conducted in both Cambridge UK and Nijmegen Netherlands with 100 of the 200 total participants recruited at each site, and data from both sites analysed together.

More detail

The INSVD study is a prospective observational cohort study in patients with cerebral small vessel disease (SVD) aimed at examining whether changes in systemic inflammation predict brain white matter damage and cognitive decline. This study is funded by a joint British Heart Foundation and Dutch Heart Foundation research grant. STUDY DESIGN --------------------------------------------- This study will be conducted at the University of Cambridge (UK) and Radboud University Medical Centre (Nijmegen, Netherlands) with 100 of the 200 total participants recruited at each site. For the Cambridge arm of the study, patients will be recruited from the clinical stroke service at Cambridge University Hospitals NHS Foundation Trust. Patients will be identified by Professor Hugh Markus (Principal Investigator), Dr Stefania Nannoni and other doctors from their clinics. For the Nijmegen arm, participants will initially be recruited from the RUN DMC cohort, and supplemented with patients from the outpatient clinic of the Neurology department of Radboud University Medical Centre. Patients will be identified by Professor Frank-Erik de Leeuw (Principal Investigator) and other doctors from their clinics. At both sites, electronic hospital records will be used to aid screening and eligibility assessments. In Nijmegen, an ECG and duplex of the carotid arteries are carried out as part of the screening procedure, since data on atrial fibrillation and large artery disease are not always up-to-date or readily available from medical records. Clinicians will check the clinical information and check eligibility against the study criteria. Stroke Research Nurses and Study Coordinators will assist in patient recruitment and receiving consent and collection of baseline data. Investigators and researchers will ensure that each trial participant is fully informed about the nature and objectives of the trial, and possible risks associated with their participation. Participants will be provided with a Participant Information Sheet explaining the rationale and nature of the study, study procedures and potential benefits and risks of taking part. They will be given an opportunity to ask questions about the study. Phlebotomy and clinical assessment and cognitive testing will take place in the stroke clinic setting. MRI scanning will be done on identical scanners at the Wolfson Brain Imaging Centre, University of Cambridge, and at the Radiology department of Radboud University Medical Centre. * At baseline, subjects will undergo clinical assessment, neurological and cardiovascular examination, cognitive testing, motor assessment, blood taking for immune phenotyping and MRI brain. * At 2 years, subjects will undergo clinical assessment, neurological and cardiovascular examination, cognitive testing, motor assessment, and MRI brain. We will continue to follow-up subjects every two years with clinical and cognitive assessments to determine the presence or absence of stroke and dementia for 6 years, via separate funding. AIMS AND HYPOTHESIS --------------------------------------------- Our overarching aim is to identify specific components of the dysregulated immune response in SVD, which relate to disease progression, and can be targeted by specific therapeutic interventions. The study hypothesis is that long-term activation of the immune system, subsequent blood brain barrier (BBB) leakage and chronic neuroinflammation initiates and accelerates SVD, which compromises structural and functional brain integrity, leading to progressive white matter damage and accelerates vascular cognitive impairment. We propose an integrative approach, combining comprehensive immunophenotyping of the peripheral blood immune compartment with advanced neuroimaging biomarkers of SVD, and blood brain barrier permeability. To test our hypothesis, we will address the following key research questions: 1. Does immune reprogramming, determined by detailed immune phenotpying in the peripheral circulation, predict white matter damage in SVD and its progression? 2. What are the relationships between systemic immune changes in SVD, and BBB leakage? OBJECTIVES --------------------------------------------- Primary objectives: * To determine whether changes in immune cell function and phenotype identified in the systemic circulation predict disease progression in SVD, as measured by diffusion tensor imaging (DTI)-MRI * To determine the pattern of systemic immune changes which occur in SVD * To determine whether this pattern predicts disease progression, as measured by white matter damage on DTI Secondary objectives: * To characterise the alteration in immune phenotype occurring in SVD and how these relate to clinical, neurocognitive and imaging parameters. * To determine the relationships between systemic immune changes in SVD, and BBB leakage.

Cerebral Small Vessel DiseasesInflammationStroke

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 40 Years and over
  • Who can join: All genders

Biomarkers mentioned

eGFR

What the study is looking for

  • ✓Have given written agreement to take part to participate
  • ✓Be aged 40 years and over
  • ✓Have causing symptoms cerebral small vessel disease (SVD) defined as:
  • ✓Clinical lacunar stroke syndrome with lacunar infarct, as defined by the Standards for Reporting Vascular Changes on...
  • ✓And/OR Symptoms of cognitive impairment due to SVD with lacunar infarct on MRI

Who cannot take part

  • ✗Unable/unwilling to consent including lack of capacity to consent
  • ✗Contraindications to taking part in MRI study as assessed by the local MRI safety questionnaire, e.g., pacemaker
  • ✗Vaccination or infection with fever in preceding month
  • ✗Any stroke cause other than SVD including:
  • ✗Cardioembolic source
See the full criteria
Inclusion Criteria: * Have given written informed consent to participate * Be aged 40 years and over * Have symptomatic cerebral small vessel disease (SVD) defined as: * Clinical lacunar stroke syndrome with lacunar infarct, as defined by the Standards for Reporting Vascular Changes on Neuroimaging (STRIVE) criteria * And/OR Symptoms of cognitive impairment due to SVD with lacunar infarct on MRI * And/OR Gait apraxia/motor impairment presumed due to SVD with lacunar infarct on MRI Exclusion Criteria: * Unable/unwilling to consent including lack of capacity to consent * Contraindications to taking part in MRI study as assessed by the local MRI safety questionnaire, e.g., pacemaker * Vaccination or infection with fever in preceding month * Any stroke cause other than SVD including: * Cardioembolic source * Carotid or vertebral stenosis \> 50% measured on NASCET (North American Symptomatic Carotid Endarterectomy Trial) criteria * Myocardial infarction in past year * Auto-immune/auto-inflammatory disease * Use of immunomodulating drugs * Estimated glomerular filtration rate (eGFR) =\<59 ml/min/1.73m2 within past 3 months for Cambridge, and eGFR =\<29 ml/min/1.73m2 within past 3 months for Nijmegen, in line with local guidelines. Estimated GFR will be calculated using the Modification of Diet in Renal Disease (MDRD) equation: 186 x (Creatinine / 88.4)-1.154 x (Age)- 0.203 x (0.742 if female) x (1.210 if black). Creatinine will be checked within 3 months of the MRI, and if this has not been done as part of clinical care it will be performed as a research procedure. * Another diagnosed chronic neurological condition (e.g. Alzheimer's, Parkinson's disease, motor neurone disease, multiple sclerosis). * Limited life expectancy due to another illness or chronic condition making the 2-year follow-up difficult (e.g. widespread malignancy). * Known monogenic cause of small vessel disease (e.g. CADASIL - Cerebral Autosomal Dominant Arteriopathy with Sub-cortical Infarcts and Leukoencephalopathy)

Where Is This Study? (1 UK site)

University of Cambridge

Cambridge CB2 0QQ, United Kingdom

Recruiting
Site contact (verified)
Hugh S MarkusPrincipal Investigator

How to Get in Touch

Hugh S Markus

Sponsor contact

CONTACT

+44 (0)1223 856661 hsm32@medschl.cam.ac.uk

Audrey Low

Sponsor contact

CONTACT

+44 (0) 1223 216619 al927@medschl.cam.ac.uk
Data sourced from ClinicalTrials.gov · Last verified: 2023-02